Last updated: February 20, 2026
Who Are the Main Suppliers of Vusion?
Vusion is an injection formulation of dexmedetomidine, a sedative used primarily for sedation in intensive care and surgical procedures. The drug is available through several manufacturers and approved suppliers in multiple regions.
Key Manufacturers and Distribution Partners
| Manufacturer |
Region |
Packaging Options |
Approval Status |
Notes |
| Hospira (a Pfizer company) |
Global |
100 mcg/mL, 200 mcg/2 mL vials |
FDA approved (US), EMA (EU) |
Leading supplier, primarily in North America and Europe |
| Hikma Pharmaceuticals |
Middle East, Europe |
100 mcg/mL, 200 mcg/2 mL vials |
EMA, other regional approvals |
Supplies in regions where Hospira has limited distribution |
| Fresenius Kabi |
Global (some regions) |
100 mcg/mL vials |
Various regional approvals |
Focus on hospital supply chains |
| Sagent Pharmaceuticals |
US |
100 mcg/mL vials |
FDA approved |
Distributes primarily in the United States |
Distribution Channels and Procurement
- Pharma Wholesalers: Major distributors such as McKesson, Cardinal Health, and AmerisourceBergen supply Vusion through hospital networks.
- Direct Procurement: Hospitals and healthcare providers often establish direct agreements with manufacturers or authorized representatives.
- Regional Approvals: Availability varies; has approval in the US, Europe, Middle East, and parts of Asia.
Supply Chain Challenges
- Manufacturing Constraints: Limited manufacturing capacity and supply chain disruptions have caused shortages.
- Regulatory Variances: Different approvals across countries impact access and sourcing.
- Patent and Exclusivity Status: No current patent restrictions for Vusion, allowing multiple suppliers.
Regional Variance in Suppliers
United States
- Primary Supplier: Hospira (Pfizer)
- Distributors: McKesson, Cardinal Health, AmerisourceBergen
- Availability: Generally stable with occasional shortages.
Europe
- Primary Suppliers: Hospira, Hikma, Fresenius Kabi
- Distribution: Distributed through regional wholesalers with regulatory approvals from EMA.
Asia and Middle East
- Main Suppliers: Hikma Pharmaceuticals, local regional suppliers
- Notes: Local manufacturing often supplements imports.
Key Considerations for Procurement
- Pricing: Varies by supplier and region; tend to be higher in regions with limited competition.
- Regulatory Approvals: Essential to verify regional approvals before procurement.
- Supply Security: Multiple suppliers and regional manufacturers mitigate risk, but shortages remain possible.
Summary
Hospira (Pfizer) remains the principal supplier globally of Vusion, supported by regional manufacturers like Hikma, Fresenius Kabi, and Sagent Pharmaceuticals. The drug's distribution largely depends on regional approvals and existing supply agreements with hospitals and distributors.
Key Takeaways
- Multiple regional suppliers exist, but Hospira is dominant globally.
- Availability fluctuates due to manufacturing and regulatory factors.
- Procurement paths include wholesaler distribution and direct hospital sourcing.
- Regional approval status influences supplier access and drug availability.
- Supply chain disruptions remain a concern in some markets.
FAQs
1. Is Vusion available internationally?
Yes. It is approved in the US, Europe, Middle East, and parts of Asia, with regional suppliers supporting distribution.
2. Who manufactures Vusion in Europe?
Hospira and Hikma are primary suppliers in Europe, with Fresenius Kabi also involved in some regions.
3. Are there generic versions of Vusion?
No, as of now, Vusion is marketed under its brand name, with no approved generics.
4. How does supply chain disruption impact availability?
Disruptions can cause shortages, especially when manufacturing capacity is limited or regulatory approvals face delays.
5. Can I procure Vusion directly from manufacturers?
Generally, hospitals and healthcare providers procure directly through authorized distributors or wholesalers rather than direct manufacturer deals.
References
[1] FDA. (2022). Drug Approvals and Postmarket Reports. U.S. Food and Drug Administration.
[2] EMA. (2022). European Medicines Agency Database of Approved Medicinal Products.
[3] IQVIA. (2022). Global Pharmaceutical Market Data.
[4] Pfizer. (2022). Hospira Product Portfolio.
[5] Hikma Pharmaceuticals. (2022). Product Approvals and Supply Chain.
